Cancer vaccine

GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference

Retrieved on: 
Wednesday, March 10, 2021
Medical specialties, Medicine, Clinical medicine, Vaccination, Vaccines, Vaccine, Virology, Immunotherapy, Cancer immunotherapy, Cancer vaccine, Cancer, HIV vaccine development

(NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, has been invited to present at Maxim Groups Inaugural Emerging Growth Virtual Conference to be held March 17-18.

Key Points: 
  • (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, has been invited to present at Maxim Groups Inaugural Emerging Growth Virtual Conference to be held March 17-18.
  • During this virtual conference, GeoVaxs Chairman and CEO, David Dodd, will present an overview of GeoVaxs immunotherapy and vaccine research and development efforts, focusing on the Companys COVID-19 and cancer immunotherapy programs.
  • GeoVaxs Chief Scientific Officer, Mark Newman, PhD, will also participate in a panel discussion on recent developments in cancer vaccines and immuno-oncology.
  • GeoVaxs HIV vaccine is also part of two separate collaborative efforts to apply its innovative gene therapy approach toward a functional cure for HIV.

Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs

Retrieved on: 
Wednesday, March 3, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Immunotherapy, Virotherapy, Cancer vaccine, Biotechnology, Cancer vaccines

PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing.

Key Points: 
  • PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing.
  • In conjunction with the financing, Mr. Sangwoo Lee, Managing Director Korea Investment Partners USA Inc. joined Geneos' Board of Directors.
  • "Geneos has made great strides in advancing the novel and differentiated GT-EPIC platform for personalized cancer treatments," commented Mr. Lee.
  • "The Series A1 financing demonstrates our investors' confidence in the GT-EPIC platform to design and manufacture patient-specific personalized cancer vaccines," said Dr. Niranjan Y. Sardesai, Founder and Chief Executive Officer of Geneos Therapeutics.

NexImmune to Present at the 2021 Barclays Global Healthcare Conference

Retrieved on: 
Tuesday, March 2, 2021
Medical specialties, Clinical medicine, Branches of biology, Immunology, Immune system, Cancer immunotherapy, Immunotherapy, Virotherapy, Immunoglobulin E, T cell, Cancer vaccine, Active immunotherapy

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced thatScott Carmer, Chief Executive Officer, will present a company overview at thevirtual 2021 Barclays Global Healthcare Conference onThursday, March 11, 2021at10:55 a.m. Eastern time.

Key Points: 
  • GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced thatScott Carmer, Chief Executive Officer, will present a company overview at thevirtual 2021 Barclays Global Healthcare Conference onThursday, March 11, 2021at10:55 a.m. Eastern time.
  • The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations .
  • A replay will be available on the NexImmune website following the presentation.
  • NexImmune, based inGaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology.

Increasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer Patients

Retrieved on: 
Thursday, February 18, 2021
Vaccination, Medical specialties, Clinical medicine, Cancer vaccines, Medicine, Vaccines, Virology, Vaccine, Therapeutic vaccines, Cancer vaccine, HPV vaccine, Cancer prevention

Ovarian cancer is regarded as one of the most common types of cancer among women.

Key Points: 
  • Ovarian cancer is regarded as one of the most common types of cancer among women.
  • The report said that: "(The) growth of the cancer vaccines market is attributed to rise in number of cancer patients across the globe.
  • Furthermore, rise in public awareness toward benefits of cancer vaccines, surge in demand for cancer vaccines, and rise in adoption rate of preventive and therapeutic vaccines are other factors that contribute toward growth of the market."
  • Moreover, rise in adoption rates of preventive and therapeutic vaccines, technological advancements in cancer vaccines, increase in number of cancer cases, and launch of novel cancer vaccines further boost the cancer vaccines market growth Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines is expected to offer lucrative opportunities in the near future."

Increasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer Patients

Retrieved on: 
Thursday, February 18, 2021
Vaccination, Medical specialties, Clinical medicine, Cancer vaccines, Medicine, Vaccines, Virology, Vaccine, Therapeutic vaccines, Cancer vaccine, HPV vaccine, Cancer prevention

Ovarian cancer is regarded as one of the most common types of cancer among women.

Key Points: 
  • Ovarian cancer is regarded as one of the most common types of cancer among women.
  • The report said that: "(The) growth of the cancer vaccines market is attributed to rise in number of cancer patients across the globe.
  • Furthermore, rise in public awareness toward benefits of cancer vaccines, surge in demand for cancer vaccines, and rise in adoption rate of preventive and therapeutic vaccines are other factors that contribute toward growth of the market."
  • Moreover, rise in adoption rates of preventive and therapeutic vaccines, technological advancements in cancer vaccines, increase in number of cancer cases, and launch of novel cancer vaccines further boost the cancer vaccines market growth Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines is expected to offer lucrative opportunities in the near future."

Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Market Insight 2026

Retrieved on: 
Wednesday, February 17, 2021
Medical specialties, Clinical medicine, Medicine, Vaccination, Cancer vaccines, Vaccines, Cancer immunotherapy, Immunotherapy, Virotherapy, Vaccine, Cancer vaccine, Dendritic cell

NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    Global dendritic cell cancer vaccine immunotherapy for the patients is estimated to deliver ample trends and opportunities as well as experiences that are life-changing for the patients who will receive the drugs that will be available within the market.
  • As per the extensive research conducted for current market trend and opportunities, it is estimated that the therapy in a very progressive way could transform the entire cancer therapeutics market towards the benefits of immunotherapy.
  • Some of the current drivers found to be the reason for accelerating the market are: successful implication of immunotherapy applications among the cancer patients, high-failure rate of other therapies, increased prevalence and mortality rate of cancer and increased awareness of the patient population towards successful clinical investigations for dendritic cell cancer vaccine immunotherapy all across the globe.
  • The performance of the therapy is now getting reflected as a top emerging leader, thus leaning the entire cancer therapeutics market towards the applications of dendritic cell cancer vaccine immunotherapy which subsequently involves dendritic cell, an important cell of immune system for generating a strong immune response against the cancer cells.

Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Market Insight 2026

Retrieved on: 
Wednesday, February 17, 2021
Medical specialties, Clinical medicine, Medicine, Vaccination, Cancer vaccines, Vaccines, Cancer immunotherapy, Immunotherapy, Virotherapy, Vaccine, Cancer vaccine, Dendritic cell

NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    Global dendritic cell cancer vaccine immunotherapy for the patients is estimated to deliver ample trends and opportunities as well as experiences that are life-changing for the patients who will receive the drugs that will be available within the market.
  • As per the extensive research conducted for current market trend and opportunities, it is estimated that the therapy in a very progressive way could transform the entire cancer therapeutics market towards the benefits of immunotherapy.
  • Some of the current drivers found to be the reason for accelerating the market are: successful implication of immunotherapy applications among the cancer patients, high-failure rate of other therapies, increased prevalence and mortality rate of cancer and increased awareness of the patient population towards successful clinical investigations for dendritic cell cancer vaccine immunotherapy all across the globe.
  • The performance of the therapy is now getting reflected as a top emerging leader, thus leaning the entire cancer therapeutics market towards the applications of dendritic cell cancer vaccine immunotherapy which subsequently involves dendritic cell, an important cell of immune system for generating a strong immune response against the cancer cells.

Global Tumor Infiltrating Lymphocytes TIL Cancer Immunotherapy Market Trends Insight Report 2025

Retrieved on: 
Wednesday, February 17, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Lymphocytes, Tumor-infiltrating lymphocytes, Immunotherapy, Cancer vaccine, Cancer immunotherapy, Interleukin 2

NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:
    Tumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies
    Expected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000
    Over the past few years, immunotherapy market at global level has been experiencing appreciation for delivering the trends and opportunities that were hardly observed by any other cancer therapeutics market.
  • As per the research conducted for global tumor infiltrating lymphocyte therapy market, it is estimated that the complete arrival of the therapy for commercial use will end the unspecifity usually observed in the global cancer therapeutics market.
  • As per the extensive research analysis, it is believed that the market in the upcoming years will be responsible for driving the future of the cancer therapeutics market by developing the trends and opportunities that will completely shift the dominant side of the cancer therapeutics market towards tumor-infiltrating lymphocyte therapy market.
  • Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026
    US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026
    US Alzheimer's Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026
    US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026
    Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025
    Bevacizumab Biosimilar Market Opportunity , Sales, Price & Clinical Trials Insight 2025
    Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026
    Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026

Global Tumor Infiltrating Lymphocytes TIL Cancer Immunotherapy Market Trends Insight Report 2025

Retrieved on: 
Wednesday, February 17, 2021
Clinical medicine, Medicine, Medical specialties, Oncology, Lymphocytes, Tumor-infiltrating lymphocytes, Immunotherapy, Cancer vaccine, Cancer immunotherapy, Interleukin 2

NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:
    Tumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies
    Expected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000
    Over the past few years, immunotherapy market at global level has been experiencing appreciation for delivering the trends and opportunities that were hardly observed by any other cancer therapeutics market.
  • As per the research conducted for global tumor infiltrating lymphocyte therapy market, it is estimated that the complete arrival of the therapy for commercial use will end the unspecifity usually observed in the global cancer therapeutics market.
  • As per the extensive research analysis, it is believed that the market in the upcoming years will be responsible for driving the future of the cancer therapeutics market by developing the trends and opportunities that will completely shift the dominant side of the cancer therapeutics market towards tumor-infiltrating lymphocyte therapy market.
  • Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026
    US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026
    US Alzheimer's Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026
    US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026
    Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025
    Bevacizumab Biosimilar Market Opportunity , Sales, Price & Clinical Trials Insight 2025
    Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026
    Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Medical specialties, Clinical medicine, Papillomavirus, Infectious causes of cancer, Vaccination, Vaccines, Gynaecological cancer, HPV vaccine, Vaccine, Human papillomavirus infection, Cancer vaccine

BioVaxys President and Chief Operating Officer Ken Kovansaid "This co-development gives BioVaxys access to Procare Health's clinical development and regulatory expertise in the EU, and to its marketing & sales presence in Europe."

Key Points: 
  • BioVaxys President and Chief Operating Officer Ken Kovansaid "This co-development gives BioVaxys access to Procare Health's clinical development and regulatory expertise in the EU, and to its marketing & sales presence in Europe."
  • The collaboration with BioVaxys will help Procare Health fuel its product offerings in the gynecological oncology field.Yann Gaslain, CEO of Procare Health stated, "We are thrilled to start working the collaboration with BioVaxys as it brings a new hope in the field of gynecological cancer.
  • BioVaxys and Procare Health will split costs for feasibility, proof-of-concept, and preclinical development for a HPV viral vaccine, as well as a cervical cancer vaccine based on the BioVaxys cancer vaccine platform.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.